Piper Sandler reaffirmed its Overweight rating on DexCom (NASDAQ:DXCM) stock, maintaining a price target of $90.00. The firm's analysts highlighted several positive developments for the medical device ...

In a report released today, Jeff Johnson from Robert W. Baird upgraded Dexcom (DXCM – Research Report) to a Buy, with a price target of ...

Abbott has won an innovation award for Lingo, its first consumer biowearable over-the-counter device to empower people in ...

Data from continuous glucose monitors can predict nerve, eye and kidney damage caused by type 1 diabetes, University of ...

A research study from the University of Virginia Center for Diabetes Technology suggests that data from continuous glucose monitors (CGMs) can predict the development of serious complications in ...